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Abstract: Natural killer (NK) cells are a population of lymphocytes which classically form part of the
innate immune system. They are defined as innate lymphocytes, due to their ability to kill infected
or transformed cells without prior activation. In addition to their cytotoxic abilities, NK cells are
also rapid producers of inflammatory cytokines such as interferon gamma (IFN-γ) and are therefore
a critical component of early immune responses. Due to these unique abilities, NK cells are a very
important component of host protection, especially anti-tumour and anti-viral immunity. Obesity is
a worldwide epidemic, with over 600 million adults and 124 million children now classified as
obese. It is well established that individuals who are obese are at a higher risk of many acute and
chronic conditions, including cancer and viral infections. Over the past 10 years, many studies have
investigated the impact of obesity on NK cell biology, detailing systemic dysregulation of NK cell
functions. More recently, several studies have investigated the role of NK cells in the homeostasis
of adipose tissue and the pathophysiology of obesity. In this review, we will discuss in detail these
studies and focus on emerging data detailing the metabolic mechanisms altering NK cells in obesity.
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1. Obesity
Obesity is classically defined as an accumulation of excess adiposity. The current strategies
for stratifying bodyweight are based on body mass index (BMI) which measures bodyweight in
kilograms and divides by height in metres squared. A BMI between 20 and 25 kg/m2 represents
a healthy bodyweight, with a BMI between 26 and 30 defining overweight, and a BMI greater than
30 classified as obese. Over 600 million adults worldwide are classified as obese, with an estimated
age-standardized prevalence of 10.8% among men and 14.9% among women [1]. For the first time,
more children are obese than underweight. This represents a 10-fold increase in childhood obesity
since 1975 [2]. The estimated age-standardized prevalence of childhood obesity is 5% [3]. We know
now that childhood obesity tracks strongly into adulthood, with up to 82% of obese children remaining
obese in adulthood [4]. Large population studies have demonstrated that obesity increases the risk
of developing numerous comorbidities, including type 2 diabetes mellitus (T2DM), cardiovascular
disease (CVD) and increased risk of many cancers [5,6]. These co-morbidities have been clearly shown
to reduce the life expectancy of the obese individual.
2. Obesity and Cancer
Cancer is a leading cause of death worldwide with 7.6 million deaths from cancer annually [7].
Recent reports from the centers for disease control and prevention (CDC) in the United States have
implicated obesity in 40% of cancer cases, representing 630,000 diagnosis in 2014 alone [8]. This is
Cancers 2019, 11, 573; doi:10.3390/cancers11040573 www.mdpi.com/journal/cancers
Cancers 2019, 11, 573 2 of 12
a finding which is mirrored in many studies around the globe [9]. The development of obesity related
cancers is multi-factorial, with many changes in hormones, adipokines, cytokines and immunity
identified. Obesity is associated with insulin resistance, a well-established pre-cursor to T2DM;
however, elevated insulin levels also promote the development of certain obesity related cancers
such as colorectal, pancreatic, liver and endometrial [10–12]. Several studies have also identified
links between leptin, an adipokine increased in obese children and adults, and cancer. Most studies
investigating leptin in the context of obesity have focused on breast cancer, where leptin can directly
stimulate the proliferation of breast tumour cells [13,14]. Another important component of cancer
development in obesity is the presence of chronic inflammation [15,16]. Numerous studies have
highlighted the links between chronic inflammation and the development of cancer [15]. Amongst the
strongest associations between inflammation and cancer is in colon carcinogenesis in patients with
inflammatory bowel disease [17].
3. Obesity and Immune Dysregulation
Obesity drives a programme of systemic inflammation, which underpins the development
of not only malignancies, but other co-morbidities such as T2DM and CVD. Several cytokines
which are elevated in obese individuals have been shown to disrupt normal homeostatic processes,
such as interleukin 1 (IL-1) and insulin signalling, or IL-17 and adipogenesis [18,19]. Obesity driven
inflammation has been shown to promote the development of liver cancer [20]. This chronic
inflammation stems primarily from a dysregulated immune system. We and many others have
identified alterations in subsets of the immune system, paired with a loss of regulation and increased
inflammatory profile [21–27]. This dysregulation is not limited to adults with established co-morbid
diseases, but is also present in obese children as young as six years of age, long before the development
of overt disease [28,29]. Supporting the fact that obesity drives chronic inflammation, which precedes
the development of co-morbid diseases including cancer. In addition to the increased inflammatory
burden, obesity negatively impacts on the bodies anti-tumour effector populations, such as Natural
Killer (NK) cells.
4. Natural Killer Cells
Natural killer cells are a subset of innate lymphocytes, which play a very important role in early
host protection [30]. They differ from classical T and B lymphocytes in that, NK cells can rapidly
respond to infected or transformed cells without prior activation, via their production of lytic molecules
such as perforins or granzymes [31]. Natural Killer cells can also shape subsequent immune responses
through their rapid production of cytokines (interferon gamma (IFN-γ), tumor necrosis factor alpha
(TNFα), IL-6 and granulocyte-macrophage colony-stimulating factor (GM-CSF)). Activation of NK cells
is tightly controlled through the expression of germline coded receptors which in response to changes
in environmental cues can alter the balance of activating and inhibitory signals, allowing the activation
of the cell. Loss of self-identifying molecules such as human leukocyte antigen (HLA) which provide an
inhibitory signal via killer-cell immunoglobulin like receptors (KIRs) will result in the activation of NK
cells, and the lysis of the target cell. Natural Killer cells can also be activated by the binding of activation
molecules such as NKG2D which are upregulated by stressed and transformed cells [32,33]. They are
therefore primed to target transformed tumour cells without prior immunological priming. In addition
to their targeting of transformed cells, NK cells can also target cancer stem cells (CSC) which can seed
metastasis and promote tumour bulk [34–37]. Activation of NK cells is not limited to the recognition
of malignant cells or CSC; NK cells can also be activated via soluble cytokines including IL-2, IL-12,
IL-15 and IL-18 [38–41]. Immunometabolism has been highlighted as a critical component of NK cell
activation, at rest NK cells metabolize glucose via glycolysis coupled to oxidative phosphorylation,
yielding high levels of energy. Upon activation, NK cells rapidly increase their rates of aerobic
glycolytic metabolism providing the biosynthetic precursors for cytokine and lytic granule production.
Clear evidence for the importance of glycolysis for NK cell effector function is demonstrated by the
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inhibition of glycolysis using 2-dexoy glucose (2DG), which results in inhibition of NK cell cytokine
production and lytic molecule production [38,42,43]. Mammalian target of rapamycin (mTOR) has
been highlighted as a master regulator of NK cell metabolism; its requirement has been demonstrated
to be essential for NK cell effector function [38,42]. Traditionally, NK cells were described as lacking
memory; however, several studies have now shown that murine NK cells can form memory [44].
In a series of very elegant studies human NK cells have been shown to under training, where an initial
cytokine stimulation results in a boosted response several days or weeks later [45,46]. This has opened
up a new therapeutic avenue for the use of trained NK cells as a potent immunotherapy.
5. Natural Killer Cells in Cancer
NK cells are a critically important component of anti-tumour immunity, as they are equipped
with potent anti-tumour machinery including cytotoxic granules, pro-inflammatory cytokines and
death-inducing ligands such as FAS ligand and TNF-related apoptosis-inducing ligand (TRAIL).
The importance of NK cells in protection from cancer is highlighted by the increased prevalence of cancer
in humans with defective NK cells such as Chediak–Higashi disease, and validated by the exacerbation of
cancer in NK cell deficient mouse models [47,48]. Studies have also highlighted associations between low
NK cell activity and cancer risk. In an 11-year longitudinal study, it was demonstrated that individuals
with low NK cell activity levels were at a higher risk of developing cancer, highlighting the importance
of NK cells in the prevention of overt malignancy and immunosurveillance [49]. Similarly, in a cohort
of 872 patients, individuals with low NK cell activity (IFN-γ production) had a 10-fold higher rick
of colorectal cancer than those with high NK cell activity [50]. Conversely, in a cohort of colorectal
patients and matched controls, expression of the high NK cell activity haplotype of NKG2D, HNK1,
was associated with decreased risk of colorectal cancer [50]. In parallel with cancer risk, several studies
have highlighted the importance of NK cells in the prognosis of patients with cancer [51–53]. In a cohort
of 50 patients with primary squamous cell lung carcinoma, increased tumour infiltrating NK cell
frequency was correlated with improved prognosis [51]. Similarly, in a cohort of patients with
colorectal carcinoma, high NK cell infiltration into the tumour was associated with a favourable
outcome [52]. Cancer can also induce defects in NK cells, using a KRAS mutation model of pancreatic
cancer, Kaur and colleagues highlighted defects in NK cell frequencies and functions during the
pre-neoplastic stage of pancreatic cancer, suggesting that cancer induces early defects in NK cells
which allows the progression and expansion of the disease. In the same study, diet induced obesity
compounded the alteration of NK cells in the tumour microenvironment, which promoted the expansion
of pancreatic tumours [54]. This is supported by studies which investigated NK cell functions in
patients with acute myeloid leukaemia (AML) which reported that NK cells were dysfunctional with
reduced cytokine production and degranulation. Incubation of NK cells isolated from healthy donors
with AML blasts induced similar defects suggesting the reported defects were cancer induced [55].
Mamessier and colleagues expanded on this concept by showing that human breast cancer cells could
promote tolerance in NK cells by reducing the expression of activating receptors including NKG2D,
and that tumour derived factors such as transforming growth factor (TGF)-β1 directly reduced NK
cell activity [56]. Due to their potent effector functions, NK cells represent an attractive target for
cancer immunotherapy. Several approaches have been highlighted, ranging from adoptive transfer
of NK cells into patients, cytokine therapy or targeting/modifying NK cells receptors to boost their
cancer killing function [57]. Adoptive transfer of NK cells involves the isolation of either autologous or
allogenic NK cells, followed by their expansion and activation before transfusion in the patient [58–61].
Studies investigating autologous transfer have not demonstrated clinically relevant responses [59,60].
This is due to the inability of adoptively transferred cells to lyse tumour cells unless restimulated
in vitro [60]. The allogenic approach has yielded more positive results, especially with KIR-mismatch
in patients with haematological cancers such as AML [58,61]. In a 2010 clinical trial of adoptive transfer
of allogenic NK cells, Rubnitz and colleagues presented striking data in childhood AML, showing 100%
remission rates [62]. Another approach which has shown promise it the transfer of cytokine-trained
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NK cells, this involves harnessing the training or memory potential of NK cells. Isolated NK cells
(autologous or allogenic) are activated in vitro using a cocktail of cytokines (IL-12, IL-15 and IL-18) and,
after restimulation, show boosted effector responses [46]. In a phase-I clinical trial, cytokine trained
NK cells demonstrated increased effector functions and a clinical response in five out of nine patients
with four complete remissions [63]. Collectively, these studies show the critical role for NK cells in
tumour immunity and their therapeutic potential in humans.
6. Natural Killer Cells in Obesity.
In 2009, we reported that NK cells were altered in a cohort of severely obese patients [64].
We showed that NK cell frequencies were reduced in obese patients when compared to lean counterparts,
along with alterations in the surface repertoire of NK cell activating and inhibitory molecules. In the
same cohort of patients, NK cell cytotoxic capabilities were reduced, with NK cells isolated from obese
patients killing significantly fewer of the K562 myeloid leukaemia cell line compared to healthy controls.
Several other studies have also highlighted the negative impact of obesity on NK cells [22,65–70].
In a 2017 study, Viel and colleagues reported increased expression of activation markers such as CD69
on NK cell from obese patients in parallel with a loss of function as measured by degranulation and
the production of macrophage inflammatory protein (MIP)-1β or IFN-γ [70]. NK cells resident in
tissues are also impacted by obesity, in 2017, Shoae-Hassani and colleagues showed that NK cells
resident in the adipose tissue of obese individuals expressed less NKp30 and NKp44 compared to lean
controls. To increase the understanding on when these defects are established, we investigated NK cell
frequencies and functions in a cohort of obese children aged 6–16 years of age, who were free from
overt metabolic disease but do show high levels of insulin resistance. We demonstrated alterations
in NK cell frequencies with reduction in NK cell number in obese children, in an insulin resistance
dependent manner. Furthermore, we observed defective tumour lysis by NK cells isolated from obese
children probably due to the defective production of granzyme B and perforin [67]. This suggests
defects in NK cells are seeded early in obesity before the development of overt metabolic disease.
Reassuringly, a study investigating the impact of weight loss following bariatric surgery on NK
cells, found a normalization of NK cell cytotoxicity six months post-surgery [71]. This suggests that,
with weight loss, obesity induced defects in NK cells can be reversed. This was further supported by
two studies, the first of which by Jahn and colleagues showed that weight loss in obese individuals
via diet and exercise resulted in increased IFN-γ production by NK cells [72]. In the second study,
Barra and colleagues showed that high intensity interval training (HIIT) increased NK cell frequencies
and function in obese women and mice, in addition to obesity, breast cancer cells where intravenously
injected into the mice, and it was demonstrated that HIIT reduced tumour burden, with the authors
postulating that this effect was mediated via increased NK cell activity (Figure 1) [73]. The processes
via which weight loss or high intensity training restores NK cell functions are currently unknown.
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functions. Leptin is a peptide hormone produced primarily by adipocytes. Its primary role is in the 
regulation of food intake, acting as a satiety signal [74–77]. Leptin levels are proportional to the 
adipose tissue mass, therefore are elevated in obese adults and children [28,78]. In addition to its role 
in regulation of energy homeostasis, leptin has been shown to be an important regulator of the 
immune system [79–82]. In leptin, receptor deficient mice (db/db) NK cell frequencies were reduced 
in the periphery, liver and spleen, suggesting that leptin is an important regulator of NK cell 
development [83]. In addition, the activation of NK cell was also impaired in leptin receptor deficient 
mice. In 2008, Nave and colleagues confirmed a role for leptin in the regulation of NK cells, and 
proposed a mechanism through which resistance of leptin signalling in NK cells underpinned their 
dysfunction in murine models of obesity [84]. Leptin resistance in obesity is a well-established feature 
which extends beyond the regulation of NK cells and into the classical actions of leptin in energy 
homeostasis [85,86]. In studies by Laue and colleagues, expression of the leptin receptor was found 
to be higher on NK cells from obese individuals compared to healthy controls; however, the authors 
noted diminished downstream signalling in obese donors. In the same study, leptin stimulation 
increased cytokine production (IFN-γ) in NK cells from healthy donors but not obese donors, 
although similar levels of proliferation were noted [87].  
In addition to the deleterious effect of leptin resistance, we have recently elucidated another 
mechanism which drives defective NK cells in human obesity [22]. It is now well established that NK 
cell function is intrinsically dependent on cellular metabolism, with several studies highlighting the 
absolute requirement of NK cells to engage in glycolysis and oxidative phosphorylation [42,43,88,89]. 
In our recent study, we show that NK cells isolated from obese patients dysregulated metabolism, 
with a failure to engage glycolytic metabolism. Using RNA-sequencing, we highlighted that NK cells 
from obese subjects displayed elevated expression of genes involved in lipid handling and 
Figure 1. Overview of NK cell phenotype in health and obesity (A) schematic detailing human NK
cell phenotype; surface molecules (CD56, CD16, natural killer group (NKG)2 family and killer-cell
immunoglobulin-like receptors (KIRs), cytokine receptors (Interleukin(IL)-2, IL-12, IL-15 and IL-18)
and effector molecules (cytokine and lytic olecule) production; (B) schematic detailing the impact of
obesity on NK cells (lower cell freq i s, reduced cytokine production and reduced cytotoxicity);
(C) schematic detailing t act of weight loss on NK cells (resto d frequenci s, effector molecule
production and cytotoxicit ).
The exact ec anisms via w ich obesity in uces defects in NK cells are now emerging,
several studies showed that leptin, an adipokine elevated in obese adults and children, can modulate
NK cell functions. Leptin is a peptide hormone produced primarily by adipocytes. Its primary role
is in the regulation of food intake, acting as a satiety signal [74–77]. Leptin levels are proportional
to the adipose tissue mass, therefore are elevated in obese adults and children [28,78]. In addition
to its role in regulation of energy homeostasis, leptin has been shown to be an important regulator
of the immune system [79–82]. In leptin, receptor deficient mice (db/db) NK cell frequencies were
reduced in the periphery, liver and splee , suggesting that leptin is an importan egulator of NK
cell development [83]. In addition, the activation of NK cell was also impaired in leptin receptor
deficient mice. In 2008, Nave and colleagues confirmed a role for leptin in the regulation of NK cells,
and proposed a mechanism through which resistance of leptin signalling in NK cells underpinned their
dysfunction in murine models of obesity [84]. Leptin resistance in obesity is a well-established feature
which extends beyond the regulation of NK cells and into the classical actions of leptin in energy
homeostasis [85,86]. In studies by Laue and colleagues, expression of the leptin receptor was found to
be higher on NK cells from obese individuals compared to healthy controls; however, the authors noted
diminished downstream signalling in obese donors. In the same study, leptin stimulation increased
cytokine pro uction (IFN-γ) in NK cells from healthy donors but not obese donors, although similar
levels of proliferation w re noted [87].
In addition to the deleterious effect of leptin resistance, we have recently elucidated another
mechanism which drives defective NK cells in human obesity [22]. It is now well established that NK
cell function is intrinsically dependent on cellular metabolism, with several studies highlighting the
absolute requirement of NK cells to engage in glycolysis and oxidative phosphorylation [42,43,88,89].
In our recent study, we show that NK cells isolated from obese patients dysregulated metabolism,
with a failure to engage glycolytic metabolism. Using RNA-sequencing, we highlighted that NK
cells from obese subjects displayed elevated expression of genes involved in lipid handling and
metabolism. Upon further investigation, we showed that culturing of NK cells with the free fatty acids
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(FFA), oleate and palmitate, recapitulated obesity-like defects in NK cells, with loss of tumour lysis,
blunted cytokine production and a failure to metabolically reprogramme. Using murine models of
malignancy, we show diminished anti-tumour immunity with FFA-treated NK cells, highlighting a direct
link between obesity-induced NK cell defects and cancer (Figure 2) [22].
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7. Natural Killer Cells in Adipose Tissue
In addition to their potent host protection role, NK cells also play an important role in tissue
homeostasis, at sites including the uterus and adipose depots. Strikingly, Perdu and colleagues
reported that maternal obesity resulted in defective NK cells in the uterus, with reduced numbers and
a hyper-responsiveness resulting in increased expression of decorin which can limit trophoblast survival
leading to altered placental development [68]. Recently, several studies have highlighted an important
role for NK cells in adipose tissue homeostasis and the initiation of insulin resistance [24,90–92].
In 2013, O’Rourke and colleagues investigated NK cells in human adipose tissue, showing an
increased activation profile in adipose tissue compared to NK cells from the blood; in a subsequent
study, the authors provided for the first-time evidence that NK cells could regulate adipose tissue
macrophages, suggesting a possible role in the development of insulin resistance. Systemic NK
cell ablation resulted in decreased accumulation of macrophages in the adipose tissue and modest
improvements in insulin sensitivity [93,94]. In 2015, Wensveen and colleagues eloquently demonstrated
a role for NK cells in monitoring adipose tissue stress via the expression of natural cytotoxicity receptors
(NCRs). Upon the recognition of NCRs, whose expression was upregulated on stressed adipocytes in
high fat diet (HFD) fed animals, NK cells were shown to rapidly produce IFN-γ, which promoted the
recruitment of macrophages into adipose tissue. These infiltrating macrophages, originally tasked
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with phagocytosing apoptotic adipocytes, also produced increased levels of the inflammatory cytokine
IL-1β [90]. IL-1 has been extensively implicated in insulin resistance and the pathogenesis of T2DM.
This pathogenic role of NK cells in insulin resistance was supported by subsequent studies from the
lab of Jongson Lee, who showed that HFD increased NK cell numbers and the production of the
proinflammatory cytokine TNFα, in epididymal, but not subcutaneous, adipose tissue. When NK cells
were depleted, obesity-induced insulin resistance improved in parallel with decreases in both adipose
tissue macrophage frequencies and inflammation. Conversely, expansion of NK cells following IL-15
administration or reconstitution of NK cells into NK cell deficient mice increased both adipose tissue
macrophage infiltration and inflammation, exacerbating insulin resistance [92]. In 2017, Theurich and
colleagues described a specific subset of NK cells expressing IL-6Ra and colony-stimulating factor 1
receptor (CSFR1) which were expanded in obese mice and humans and detailed their contribution
to the development of insulin resistance. Ablation of CSFR1 expressing NK cell prevented the
development of obesity and insulin resistance, providing further evidence of a homeostatic role for NK
cell in metabolism.
In 2016, O’Sullivan and colleagues detailed a role for adipose tissue resident innate lymphoid
cells (ILC), specifically ILC1, in the development of insulin resistance [91]. NK cells are part of
the ILC1 lineage, but the authors showed that ILC1 in the adipose tissue where phenotypically
distinct from classical NK cells. In agreement with this, we have shown that, under steady state
conditions, ILC1s are enriched in the adipose tissue from both mice and humans, and these cells
display an adipose tissue specific phenotype. We show that these ILCs can regulate adipose tissue
macrophages via their ability to kill inflammatory macrophages. Adipose tissue macrophages express
the NKG2D ligand Rae-1, making them a target for NK cell lysis. Upon the initiation of high fat feeding,
NK cells lost their ability to kill macrophages and increased their production of IFN-γ which promoted
the recruitment of inflammatory macrophages, promoting obesity related metabolic defects [24].
Collectively, these studies provide strong evidence that NK cells are involved in the initiation of the
macrophage-driven inflammatory phenotype reported in obese adipose tissue.
8. Future Directives and Open Questions
Obesity is a worldwide epidemic and is strongly associated with a milieu of chronic diseases
including type II diabetes mellitus, cardiovascular disease and many cancers. NK cells represent an
important front-line effector cell in host protection, including tumour surveillance and clearance. NK cell
immunotherapy represents a very attractive strategy for treating cancer, in particular blood-based
cancers. In this review, we have outlined the negative impact of obesity from childhood through to
adulthood on NK cell function. It appears that the obese-micro environment drives defects in NK
cell metabolism resulting in functional failures. As a result, there may be doubt about whether NK
cell immunotherapies will be viable in obese patients. Further investigations in murine models of
obesity and obese patients will be needed to definitively answer this question. In addition to their role
in host protection, NK cells play an important part in the maintenance of tissues including adipose
tissues. NK cells and ILC1s also directly regulate macrophages, but, with high-fat feeding, NK cells
lose this ability and also alter their regulation of adipose tissue. This results in the activation and
accumulation of inflammatory macrophages that drive insulin resistance—a key player in driving
diabetes and cancer. Whether targeting this NK-Macrophage interaction will become an option for
addressing insulin resistance and tumorigenesis remains an open question.
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